Biomedical Engineering

加拿大有660万老年人，其中50多万人患有某种形式的痴呆症，主要是阿尔茨海默病;这一数字的增长速度高于预期，与十年前相比。由于COVID-19大流行及与COVID相关的社交孤立亦已知会对个人的心理健康造成不利影响，预期其增长速度将更快。到目前为止，药物治疗对改善受影响者的认知状态几乎没有希望。痴呆症的诊断和在治疗开始时确定其亚型是至关重要的，因为穆萨维博士的研究表明，如果在早期阶段和个性化的治疗策略应用，非药物治疗更有效。该策略取决于痴呆症的严重程度，其他并发疾病Zahra Moussavi博士的加拿大研究主席Tier 1计划将使用工程驱动的方法（包括人工智能）用于在痴呆症状发作时诊断痴呆亚型，基于痴呆严重程度预测患者对特定治疗的反应，其他并发疾病（合并症）和痴呆类型，以便能够提供优化的，个性化的，有效的和非药物治疗。此外，她还拥有独特的移动的临床实验室解决方案，使所有这些努力都能为社会各界所用，而不受年龄、种族、性别和社区偏远程度的影响。穆萨维博士的研究将解开患者对不同治疗反应的一些谜团，并为更有效的个性化治疗方案铺平道路。到目前为止，她已经开发出准确的方法来预测哪些患者对脉冲疗法和电磁疗法的反应最好。Moussavi博士设想在温尼伯建立一个独特的诊断和技术先进的多维，多方面，跨学科的痴呆症（及其许多亚型）综合治疗中心，最终将导致预防痴呆症，并使衰老与健康的大脑。

Canada has 6.6 million older adults, more than half a million of whom live with some form of dementia, mostly Alzheimer's Disease; this number is increasing at a higher rate than expected and compared to a decade ago. It is expected to increase even faster due to the COVID-19 pandemic and the COVID related social isolation that is also known to adversely affect an individuals' mental health. Pharmaceutical treatments have so far offered little hope for improving the cognitive state of those impacted. Dementia diagnosis and identifying its subtypes at treatment onset is crucial because Dr. Moussavi's research has shown non-pharmaceutical treatments are more effective if applied at early stages and with personalized treatment strategies. The strategy depends on dementia severity, other concurrent diseases (comorbidities) and dementia type.Dr. Zahra Moussavi' Canada Research Chair Tier 1 program will be using engineering-driven methodologies (including artificial intelligence) for diagnosing dementia subtype at dementia symptom onset, predicting the response of a patient to a particular treatment based on dementia severity, other concurrent diseases (comorbidities) and that dementia type to enable offering an optimized, personalized, effective and non-pharmaceutical treatment. In addition, she has a unique mobile clinical laboratory solution to make all these efforts accessible to all sectors of the society regardless regardless of age, race, gender, and remoteness of the community.Dr. Moussavi's research will unlock some of the mysteries that surround the response of a patient to different treatments and paves the way for more effective personalized treatment options. So far, she has developed accurate methods for predicting which patients will best respond to pulsatile versus electromagnetic therapies.Dr. Moussavi envisions establishing a unique diagnostic and technologically advanced multidimensional, multifaceted, cross-disciplinary integrated treatment center for dementia (and its many subtypes) in Winnipeg that will eventually lead to preventing dementia and enable aging with a healthy brain.